1. United Kingdom Stocks

  2. •

    Health technology

  3. •

    Medical specialties
Kromek Group Plc

Kromek Group Plc

5.76
GBX
+0.36
(+6.67%)
3.98BMarket Cap
Feb 02Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
0.35
0.1
0.07
0.06
0.05
0.05
0.05
0.04
0.03
0.03
0.04
0.03
- -
- -
Basic EPS, GAAP
-0.08
-0.05
-0.02
-0.02
-0.02
- -
- -
-0.05
-0.01
-0.01
-0.01
-0.01
- -
- -
Free Cash Flow per Basic Share
-0.39
-0.05
-0.05
-0.03
-0.01
-0.02
-0.03
-0.02
-0.01
-0.01
- -
-0.01
- -
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
0.07
0.16
0.15
0.16
0.16
0.15
0.17
0.13
0.12
0.11
0.1
0.08
- -
0.07
Tangible Book Value per Share
0.01
0.09
0.06
0.08
0.1
0.09
0.12
0.06
0.06
0.04
0.02
0.02
- -
0.01
Basic Weighted Avg Shares
8
62
109
142
176
262
277
347
359
432
432
595
641
641
Sales/Revenue/Turnover
3
6
8
8
9
12
15
13
10
12
17
19
- -
- -
Operating Margin (%)
-145.93
-63.3
-37.82
-48.67
-41.86
-19.76
-6.24
-36.12
-57.63
-58.95
-35.39
-9.75
- -
- -
Depreciation Expense
1
1
1
2
2
3
3
3
4
4
5
5
- -
- -
Net Income, GAAP
-1
-3
-2
-2
-3
-1
-1
-17
-5
-5
-6
-3
- -
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-23.89
-53.4
-26.49
-25.79
-34.39
-9.32
-4.36
-126.07
-51.71
-40.8
-35.24
-16.97
- -
- -
Working Capital
-1
8
3
8
22
18
37
12
18
9
2
9
- -
2
LT Debt
- -
- -
- -
- -
- -
- -
6
6
7
5
5
4
- -
4
Total Equity
8
18
16
25
42
40
60
45
50
47
42
49
- -
43
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
-8.91
-24.76
-12.65
-10.53
-9.22
-2.68
-1.26
-31.38
-11.26
-10.09
-13.71
-7.25
- -
- -

Capital Structure

GBP

•

in mil. unless spec.
Oct'24
Apr'24
Oct'25
ST Debt
4
8
12
LT Borrowings
6
1
1
LT Finance Leases
4
4
3
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
600
641
642
Market Capitalization
30
43
40

Working Capital

GBP

•

in mil. unless spec.
Oct'24
Apr'24
Oct'25
Total Current Assets
22
24
21
Cash, Cash Equivalents & STI
4
- -
- -
Accounts Receivable, Net
7
10
9
Inventories
11
10
11
Total Current Liabilities
11
16
19
Payables & Accruals
- -
- -
- -
ST Debt
4
8
12
Deferred Revenue
- -
- -
- -

Growth Rates

GBP

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
- -
Free Cash Flow
- -
- -
- -
Net Income, GAAP
- -
- -
- -
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

GBP

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
19
2025
- -
- -
- -
2026
- -
- -
- -

Semi-annual Earnings Per Share

GBP

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
-0.01
2025
- -
- -
- -
2026
- -
- -
- -

Semi-annual Dividends Per Share

GBP

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
- -
2025
- -
- -
- -
2026
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Arnab Basu
Full Time Employees
162
Sector
Health technology
Industry
Medical specialties
Address
NETPark Sedgefield DU United Kingdom TS21 3FD
IPO Date
Oct 16, 2013
Website
kromek.com
Similar Companies
Intuitive Surgical, Inc. (NASDAQ:ISRG)
Boston Scientific Corporation (NYSE:BSX)
Thermo Fisher Scientific Inc (NYSE:TMO)
Illumina, Inc. (NASDAQ:ILMN)
Abbott Laboratories (NYSE:ABT)
GRAIL, Inc. (NASDAQ:GRAL)
Business
Kromek Group plc is a global technology company specializing in the design, development, and manufacture of advanced detection and imaging solutions. Its core products include high-performance radiation detection systems, medical imaging technologies, industrial inspection devices, and security screening equipment. The company provides semiconductor materials and products such as cadmium zinc telluride (CZT) detectors, gamma-ray and X-ray detection systems, portable and fixed scanning devices for border security, and nuclear measurement instruments. Kromek's offerings serve defense, nuclear, medical, and security markets with innovative sensor technologies and integrated solutions. The company operates primarily across the United Kingdom, United States, and international markets, supplying government agencies, industrial corporations, and healthcare providers. Founded in 2003 and headquartered in Keswick, Cumbria, UK, Kromek Group plc has established itself within the technology and instrumentation sector. In recent developments, Kromek has focused on enhancing its product portfolio through strategic collaborations and investment in new technology platforms aimed at expanding applications in nuclear threat detection and medical diagnostics. These include launching next-generation sensor arrays, strengthening partnerships with defense contractors, and broadening its footprint in US and European markets. The company continues to pursue both organic growth and selective acquisitions to bolster its capabilities and global presence. Overall, Kromek Group plc operates within the detection technology industry, targeting markets that require advanced radiation sensing and imaging, including homeland security, nuclear inspection, and medical imaging sectors. It maintains a robust pipeline of innovative products to meet growing security and health safety demands worldwide. The company trades under the ticker KMK.L on the London Stock Exchange.